Citius Oncology Secures $9 Million Investment to Propel Growth

Citius Oncology, Inc. (NASDAQ: CTXR), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of critical care and oncology products, has announced a significant financial development set to fuel its strategic initiatives. The company recently priced a registered direct offering, poised to bring in gross proceeds of approximately $9.0 million.

This strategic capital raise involves the issuance of 1,800,000 shares of Citius Oncology’s common stock at a purchase price of $5.00 per share.

Concurrently, the offering includes a private placement of warrants, enabling the purchase of an additional 1,800,000 shares of common stock. These warrants are structured with an exercise price of $6.00 per share, becoming immediately exercisable upon issuance and remaining valid for a period of five years from the date of issuance.

This dual approach to fundraising provides both immediate capital and potential future investment.

The gross proceeds from this offering, before deducting placement agent fees and other estimated offering expenses, are projected to be $9.0 million. Citius Oncology intends to allocate these funds towards general corporate purposes, which may include advancing its pipeline, supporting clinical trials, and enhancing operational capabilities within its critical care and oncology segments.

H.C.

Wainwright & Co. is serving as the exclusive placement agent for both the registered direct offering and the concurrent private placement, underscoring their expertise in facilitating such transactions for growth-oriented biopharmaceutical companies. The closing of these offerings is anticipated to occur on or about September 6, 2025, subject to customary closing conditions.

The shares of common stock and the accompanying warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No.

333-270831), which was previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on April 3, 2023. A prospectus supplement relating to the offering has also been filed with the SEC and is available on the SEC's website at www.sec.gov.

It is important to note that this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.